Rhett JM - Search Results

1

Biology, pathology, and therapeutic targeting of RAS.

Rhett JM, Khan I, O'Bryan JP. Rhett JM, et al. Adv Cancer Res. 2020;148:69-146. doi: 10.1016/bs.acr.2020.05.002. Epub 2020 Jul 9. Adv Cancer Res. 2020. PMID: 32723567 Free PMC article. Review.

2

Therapeutic targeting of RAS: New hope for drugging the "undruggable".

Khan I, Rhett JM, O'Bryan JP. Khan I, et al. Among authors: rhett jm. Biochim Biophys Acta Mol Cell Res. 2020 Feb;1867(2):118570. doi: 10.1016/j.bbamcr.2019.118570. Epub 2019 Oct 31. Biochim Biophys Acta Mol Cell Res. 2020. PMID: 31678118 Free PMC article. Review.

3

Identification of the nucleotide-free state as a therapeutic vulnerability for inhibition of selected oncogenic RAS mutants.

Khan I, Koide A, Zuberi M, Ketavarapu G, Denbaum E, Teng KW, Rhett JM, Spencer-Smith R, Hobbs GA, Camp ER, Koide S, O'Bryan JP. Khan I, et al. Among authors: rhett jm. Cell Rep. 2022 Feb 8;38(6):110322. doi: 10.1016/j.celrep.2022.110322. Cell Rep. 2022. PMID: 35139380 Free PMC article.

4

Targeting connexin 43 with α-connexin carboxyl-terminal (ACT1) peptide enhances the activity of the targeted inhibitors, tamoxifen and lapatinib, in breast cancer: clinical implication for ACT1.

Grek CL, Rhett JM, Bruce JS, Abt MA, Ghatnekar GS, Yeh ES. Grek CL, et al. Among authors: rhett jm. BMC Cancer. 2015 Apr 3;15:296. doi: 10.1186/s12885-015-1229-6. BMC Cancer. 2015. PMID: 25881004 Free PMC article.

5

Connexin 43, breast cancer tumor suppressor: Missed connections?

Grek CL, Rhett JM, Bruce JS, Ghatnekar GS, Yeh ES. Grek CL, et al. Among authors: rhett jm. Cancer Lett. 2016 Apr 28;374(1):117-126. doi: 10.1016/j.canlet.2016.02.008. Epub 2016 Feb 13. Cancer Lett. 2016. PMID: 26884256 Review.

6

Cardiac to cancer: connecting connexins to clinical opportunity.

Grek CL, Rhett JM, Ghatnekar GS. Grek CL, et al. Among authors: rhett jm. FEBS Lett. 2014 Apr 17;588(8):1349-64. doi: 10.1016/j.febslet.2014.02.047. Epub 2014 Mar 4. FEBS Lett. 2014. PMID: 24607540 Free PMC article. Review.

7

The Potential for Connexin Hemichannels to Drive Breast Cancer Progression through Regulation of the Inflammatory Response.

Rhett JM, Yeh ES. Rhett JM, et al. Int J Mol Sci. 2018 Mar 30;19(4):1043. doi: 10.3390/ijms19041043. Int J Mol Sci. 2018. PMID: 29601539 Free PMC article. Review.

8

Novel therapies for scar reduction and regenerative healing of skin wounds.

Rhett JM, Ghatnekar GS, Palatinus JA, O'Quinn M, Yost MJ, Gourdie RG. Rhett JM, et al. Trends Biotechnol. 2008 Apr;26(4):173-80. doi: 10.1016/j.tibtech.2007.12.007. Epub 2008 Mar 4. Trends Biotechnol. 2008. PMID: 18295916 Review.

9

Purinergic signaling in early inflammatory events of the foreign body response: modulating extracellular ATP as an enabling technology for engineered implants and tissues.

Rhett JM, Fann SA, Yost MJ. Rhett JM, et al. Tissue Eng Part B Rev. 2014 Oct;20(5):392-402. doi: 10.1089/ten.TEB.2013.0554. Epub 2014 Jan 16. Tissue Eng Part B Rev. 2014. PMID: 24279914 Free PMC article. Review.

10

The perinexus: sign-post on the path to a new model of cardiac conduction?

Rhett JM, Veeraraghavan R, Poelzing S, Gourdie RG. Rhett JM, et al. Trends Cardiovasc Med. 2013 Aug;23(6):222-8. doi: 10.1016/j.tcm.2012.12.005. Epub 2013 Mar 11. Trends Cardiovasc Med. 2013. PMID: 23490883 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

22 results

Search Page

Filters